Gold Standard/Elsevier Offers Timely, Transparent, Reliable Drug Pricing Data, Including Average Wholesale Price (AWP)

Amidst industry unrest due to drug pricing benchmark upheaval, Gold Standard/Elsevier to continue publishing AWP and other pricing standards

TAMPA, FL – 18 May, 2010 – Gold Standard/Elsevier, publisher of drug information databases and decision support solutions, has announced its commitment to continue publishing transparent drug pricing information, including average wholesale price (AWP) and all other current and future pricing benchmarks. This announcement comes amidst statements by other drug database suppliers indicating they will discontinue publishing AWP in 2011.

“Gold Standard reports all drug pricing standards utilized and required within the industry, and we intend to continue doing so,” stated Kay Morgan, Senior Vice President, Drug Product and Industry Standards Research and Compliance for Gold Standard/Elsevier. “We understand the frustrations felt by those who rely on AWP and expect stability and dependability from their drug databases. We look forward to providing a reliable and flexible resource for pricing industry-wide, including AWP and any new benchmarks, through our Alchemy drug database and ProspectoRx pricing analysis tool.”

Gold Standard/Elsevier supports transparent price benchmarks for payers (health plans, patients, government agencies and employers), pharmacies and other providers for prescription drugs. The company publishes reported and calculated drug prices that are clearly distinguished within the database, and adheres to strict internal policies for populating reported versus calculated pricing fields. Drug company reported prices of AWP, WAC (wholesale acquisition cost), CMS FUL (Federal Upper Limit), and Direct Price are included in Gold Standard’s database. The company’s calculated price types include: Calculated AWP 1.25 (25% mark-up), Calculated AWP 1.20 (20% mark-up), and Calculated CMS FUL.

Gold Standard/Elsevier provides comprehensive drug pricing data via its Alchemy integrated drug database and ProspectoRx web-based drug pricing and analysis tool. Both sources offer the most frequent and accurate updates in the industry. Following review and confirmation by editorial professionals, price changes are published “live” throughout the day as they are reported by drug companies. The company’s unique Price Change Indicator tracks pricing change catalysts consistently, reporting on whether the source came from the drug company’s reports, billing unit changes or errors.

“Customers of Gold Standard/Elsevier benefit from receiving new drug product and pricing data sooner due to our superior data modeling, which affords us the quickest and most efficient turnaround for price changes and industry updates,” continued Morgan.

Alchemy is an integrated drug database and drug decision support engine that fulfills the evolving medication management needs of today’s complex healthcare systems and applications. Alchemy delivers the most current and accurate drug data and decision support tools seamlessly and cost-effectively, taking users far beyond the capabilities of other drug databases.

# # #

About Gold Standard
Based in Tampa, FL, Gold Standard/Elsevier uses innovative technologies to provide a complete suite of drug information and decision support solutions. With a tenacious commitment to product quality, Gold Standard/Elsevier solutions empower healthcare organizations, professionals and consumers to meet the most pressing healthcare challenges, improve patient safety and ensure optimal outcomes. To learn more about Gold Standard/Elsevier, visit  www.goldstandard.com.

About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence,and ClinicalKey—and publishes over 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media Contact:
Tom Reller
Vice President of Global Relations, Elsevier
+1 212-462-1912
T.Reller@Elsevier.com